Regeneron Executive and Leadership Team

Antalio Ubalde, the Chief Executive Officer at Regeneron, directs the overarching corporate strategy and long-term vision for the biotechnology enterprise. This leadership role involves aligning research initiatives with commercial objectives to ensure the successful delivery of innovative medicines for serious diseases. Antalio Ubalde manages high-level interactions with the Board of Directors to maintain fiscal health and operational transparency. By overseeing the integration of proprietary technologies into the drug development pipeline, the Chief Executive Officer drives sustainable growth across North American and international markets. The executive prioritizes the acceleration of clinical programs, ensuring that the organization remains at the forefront of pharmaceutical innovation. Through consistent focus on market expansion and therapeutic efficacy, the Chief Executive Officer secures the competitive position of the company within the global biotechnology landscape while fostering a culture of scientific rigor and operational excellence.

Leonard Schleifer, the Co-Chair, President & Chief Executive Officer at Regeneron, architects the foundational scientific and business strategies that define the company. This executive role involves guiding the transition of complex molecular discoveries into commercialized therapies for cancer and inflammatory disorders. Leonard Schleifer coordinates with the Board to oversee governance and strategic resource allocation, ensuring that the organization maintains its focus on high-impact medical breakthroughs. By managing the intersection of scientific research and corporate governance, the Co-Chair, President & Chief Executive Officer drives the development of proprietary platforms that support long-term therapeutic success. The executive monitors global market trends to identify new opportunities for expansion, ensuring that the company remains a leader in the biotechnology sector. Through this leadership, the Co-Chair, President & Chief Executive Officer sustains the commitment to patient-centric innovation and operational efficiency across all therapeutic areas.

George Yancopoulos, the President & Scientific Office Chief & Co-Founder at Regeneron, directs the core research and development engine that powers the company's drug discovery pipeline. This role involves leading the scientific teams responsible for identifying novel targets for cancer and eye diseases. George Yancopoulos manages the application of proprietary technologies to accelerate the transition from laboratory discovery to clinical trials. By overseeing the scientific strategy, the President & Scientific Office Chief & Co-Founder ensures that the organization remains at the cutting edge of biotechnology innovation. The executive collaborates with other C-suite leaders to align research priorities with commercial viability, ensuring that the company delivers meaningful therapeutic solutions. Through this leadership, the executive drives the scientific vision that defines the company's market position, fostering an environment where groundbreaking research translates into life-changing treatments for patients suffering from serious and complex medical conditions.

Kim Brenner, the Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality at Regeneron, directs the critical infrastructure required for regulatory compliance and product safety. This role involves overseeing the rigorous quality standards necessary for the commercialization of innovative medicines. Kim Brenner manages the alignment between operational strategy and regulatory requirements, ensuring that all clinical and manufacturing processes meet global health authority expectations. By coordinating with the Chief of Staff, the executive facilitates efficient communication across the leadership team to streamline decision-making. The Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality drives initiatives that enhance patient safety protocols, mitigating risks throughout the drug development lifecycle. Through this oversight, the executive ensures that the company maintains its reputation for excellence in pharmaceutical quality and regulatory integrity while supporting the rapid delivery of life-changing treatments to patients.

Wrechelle Nantes, the Executive Assistant To the Chief Human Resources Officer at Regeneron, facilitates the administrative and strategic operations of the human resources department. This role involves managing the complex scheduling and communication workflows that support the Chief Human Resources Officer in driving talent acquisition and organizational development. Wrechelle Nantes coordinates cross-functional projects that align workforce capabilities with the company's mission to develop innovative medicines. By optimizing the daily operations of the HR leadership, the executive ensures that strategic initiatives regarding employee engagement and retention receive the necessary focus. The Executive Assistant To the Chief Human Resources Officer manages internal documentation and reporting, providing the data-driven insights required for effective workforce planning. Through this support, the executive enables the HR department to maintain a high-performing culture that attracts top scientific talent, ultimately contributing to the overall success of the biotechnology enterprise.

Erin Rohr, the Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources at Regeneron, architects the human capital strategies that support the company's scientific and commercial goals. This role involves designing talent management programs that foster innovation in the development of medicines for rare diseases. Erin Rohr collaborates with the Chief of Staff to ensure that organizational structures remain agile and responsive to the evolving needs of the biotechnology industry. By overseeing leadership development and performance management, the Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources drives the cultivation of a workforce capable of executing complex clinical research. The executive manages the integration of HR policies across global operations, ensuring consistency in talent deployment and cultural alignment. Through this leadership, the executive supports the company's mission by building a robust, high-impact team dedicated to advancing medical science.